Alpha Compute Corp · NASDAQ:ALP
Alpha Compute — Portage Biotech — Investor Presentation (January 2023)
26 slides from Alpha Compute's investor presentation, Jan 6, 2023
Slide 1: Corporate Presentation January 2023
1 Corporate Presentation Nasdaq: PRTG January 2023
Slide 2: Legal Disclaimer
2 Legal Disclaimer This presentation is for information purposes only . This presentation does not constitute a general advertisement or general solicitation or an offer to sell or a solicitation to buy any securities in any jurisdiction . Such an offer can only be made by prospectus or other author
Slide 3: Immuno-Oncology Company with Four First/Best in Class Small Molecules in the Clinic
3 Immuno - Oncology Company with Four First/Best in Class Small Molecules in the Clinic iNKT Agonist: Potential 1 st Therapeutic to Increase PD - L1 Expression & PD - 1 Effectiveness Potential Best - In - Class Adenosine (A2A/A2B) Inhibitors, a Validated Mechanism of Action Multiple Phase 1b/2 Data
Slide 4: Proven Leadership with Oncology and Financing Expertise
4 Allan Shaw CFO Justin Fairchild VP Clin Dev Proven Leadership with Oncology and Financing Expertise Board of Directors Gregory Bailey, MD Rob Glassman, MD Linda M. Kozick Jim Mellon Mark Simon Ian Walters, MD CEO, Chairman Rob Kramer, PhD CSO Steve Innaimo VP PM & Operations Brian Wiley CBO Steven
Slide 5: Our Formula for Success
5 Our Formula for Success De - Risked Development Structured to Create Significant Value Strong Academic & Industry Network Developing First/Best in Class I/O Agents Potential for Large Returns • Compounds with broad targets & single agent activity • Address ~70 - 80% of patients that don’t respond
Slide 6: iNKT agonists PORT-2
iNKT agonists PORT - 2, PORT - 3 Activating the innate, adaptive immune system and correcting the TME
Slide 7: Portage's iNKT Agonist (PORT-2): Rationally Designed Liposomal Formulation of IMM60
7 Portage’s iNKT Agonist (PORT - 2): Rationally Designed Liposomal Formulation of IMM60 iNKT cell iNKT in charged liposome to protect lipid chain, aggregate in tumor, and promote Type 1 cytokine release IMM60 Binds to CD1d on APC and other myeloid cells TCR CD1d PORT 2 Immune activation
Slide 8: PORT-2 Stimulates Multiple Arms of the Immune System
8 Innate Immune System: Adaptive Immune System: Tumor Microenvironment: Kills cancer cells & increased PD - L1 expression iNKT cell PORT - 2 Stimulates Multiple Arms of the Immune System to Produce a Robust Anti - Cancer Response
Slide 9: Multiple Cell Types Involved with Anti-Cancer Response
9 Target Cells NK cell Dendritic cell B - cell CD - 8 T cell MDSC & TAM Antigen Companies in the space PD - 1 PD - L1 Tumor Cell • Upregulates PD - L1 • Monotherapy activity in PD - 1 resistant models • Combo restores sensitivity to PD - 1 Ab + Enhanced activation Multiple Cell Types Involved with A
Slide 10: PORT-2 Demonstrates Superior Response Versus PD-1 Antibody
10 Source: Jukes et al Eur. J. Immunol. 2016. 00: 1 – 11 PORT - 2 Demonstrates Superior Response Versus PD - 1 Antibody IMM60 (0.5ng/mouse) PORT - 2 Vehicle + anti PD - 1 Vehicle Untreated PORT - 2 shows better response rates vs. anti - PD - 1 in melanoma animals B16 melanoma lung metastases
Slide 11: Interim Phase I Data Confirms PORT-2 Activity & Shows Good Safety (SITC 2022)
11 Interim Phase I Data Confirms PORT - 2 Activity & Shows Good Safety (SITC 2022) SITC 2022 a Wennhold et al., Cancer Immunol Res 2021;9:1098 - 108. Tumor type 2 Melanoma 4 NSCLC Age 64 (41,79) Median prior therapies 5(3,7) Prior PD - 1 100% Performance status 50% ECOG 0 50% ECOG 1 Exposure/Safety:
Slide 12: IMPORT-201: Phase 2 Evaluates Front Line NSCLC and Refractory Melanoma
Multi - arm study with four Phase 2 readouts in 2023/2024 12 Source: https:// www.isrctn.com/ISRCTN80472712 IMPORT - 201: Phase 2 Evaluates Front Line NSCLC and Refractory Melanoma PD - 1 q3wk iv infusions n=15 PD - 1 naïve patients PORT - 2 One dose @ MTD n=15 PORT - 2 + PD - 1 6 x iv infusions q3w
Slide 13: Adenosine Portfolio
Adenosine Portfolio Unique position to modulate adenosine in 4 different ways PORT - 6 A2AR Inhibitor PORT - 7 A2BR Inhibitor PORT - 8 A2AR/A2BR Dual Inhibitor PORT - 9 Gut - Restricted A2BR Inhibitor Adenosine agents in development by many Pharma & Biotech • Validated mechanism impacting multiple i
Slide 14: Leveraging A2A and A2B Alone or in Combo Allows for Customization of Treatment
14 Targeting Adenosine in Cancer Immunotherapy to Enhance T - Cell Function; Virgano, et al; Frontiers in Immunology 2019 modified slightly and used under CC BY 4.0 Leveraging A2A and A2B Alone or in Combo Allows for Customization of Treatment Macrophage Treg T cell NK Cell Endothelial Cell CAF MDSC
Slide 15: Difference in A2A Small Molecules
15 Difference in A2A Small Molecules Only asset with single agent activity in mouse models Competitive inhibitors won’t block in settings of high adenosine ARCUS CORVUS Potency Selectivity 2.5 hrs Portage’s PORT - 6 is best in class for potency, selectivity and durability Relative profiles of A2A an
Slide 16: Fast Follower with Superior Profile Offers Major Competitive Advantages
16 iTEOS independent monotherapy activity in biomarker defined population (data from retrospective analysis ASCO 2021) Fast Follower with Superior Profile Offers Major Competitive Advantages Use biomarker and clinical data to enrich patient population Tumors with High Adenosine * Expression data fro
Slide 17: PORT-7: Highly Selective and Potent A2B Adenosine Receptor Antagonist
17 Data on File PORT - 7: Highly Selective and Potent A2B Adenosine Receptor Antagonist High potency and selectivity may provide important safety and efficacy advantages • Activity in 4T1, CT26, and other disease models (asthma, fibrosis, sickle cell) • IND approved for pro - drug Binding Affinity F
Slide 18: ADPORT-601: Adaptive Phase 1a/1b Study
18 ADPORT - 601: Adaptive Phase 1a/1b Study Phase 1a Starting Dose (10 mg BID) (n=12 - 15) A2AR (PORT - 6) indications: A2BR (PORT - 7) indications: Colorectal Cancer, Non - small Cell Lung Cancer, Endometrial Cancer, Ovarian Cancer with high A2B expression Prostate Cancer, Non - small Cell Lung Can
Slide 19: Strong U.S. and Global IP Positions on Platforms and Products
19 iNKT Agonists • Composition, formulations with antigens, other I/O agents • Liposomes/particles 2031 - 2036 Patent Exclusivity Many Applications Pending Worldwide Strong U.S. and Global IP Positions on Platforms and Products Broad and deep intellectual property covering: >60 Issued Patents Adenos
Slide 20: Pipeline
20 PLATFORM TECHNOLOGY ASSET INDICATION STAGE # of PTS PORT - 2 iNKT Agonists Liposomal Formulations IMM60 Melanoma + NSCLC 18 ASCO 23 ᬚ PORT - 2 iNKT Agonists Liposomal Formulations IMM60 Refractory Melanoma 10 ASCO 23/24 SITC 23/24 ᬛ PORT - 2 iNKT Agonists Liposomal Formulations IMM60 + Keytruda ®
Slide 21: Summary Financial Data
^Portage has the right (sole discretion/no obligation), to sell up to $30 million shares over agreement’s 36 - month term based on prevailing market prices at the time of each sale, subject to certain conditions *Includes ~3.5M Shares subject to lock - up agreements (6 - 12 mo) in recent 2 stock tra
Slide 22: Accelerating I/O Development in Untapped Growth Areas
22 Novel, Clinical Stage I/O Portfolio with Small Molecule Focus • Manufacturing simplicity, low capital investment • Nine phase 1b/2 clinical data reads over next 2 years Engine for Efficient Drug Development & Commercialization • Expert scientific oversight • Lean structure with financial flexibil
Slide 23: Appendix
Appendix
Slide 24: IMPORT-01: Dose Escalation with Best-in-Class Design for NSCLC and Melanoma
24 Source: https:// www.isrctn.com/ISRCTN80472712 IMPORT - 201: Dose Escalation with Best - in - Class Design for NSCLC and Melanoma PORT - 2 PORT - 2 + PD - 1 Phase 1 in refractory melanoma and NSCLC Phase 1/2 Trial Primary investigator Mark Middleton, Churchill Hospital, Oxford: 3 additional sites
Slide 25: PORT-6: Potential Best-in-Class A2A - Better Selectivity, Potency, Durability
25 PORT - 6: Potential Best - in - Class A2A - Better Selectivity, Potency, Durability 1 Data on File 2 AACR 2019 3 Cancer Immunology Research 2018 4 ASCO GU 2020, SITC 2018 Key Parameters PORT - 6 Portage 1 EOS - 850 iTeos 2 CPI - 444 Corvus 3 AB928 Arcus 4 Significance Potency (cAMP functional inh
Slide 26: Key Upcoming Clinical Development Milestones
26 Key Upcoming Clinical Development Milestones* 2022 2023 2024 Q4 Q1 Q2 Q3 Q4 1H 2H IMPORT - 201 (PORT - 2) P2 start PORT - 5 IND submission IMPORT - 201 (PORT - 2) P2 ORR data ADPORT - 601 (Port - 6/7) study activation ADPORT - 601 (Port - 6/7) P1b start IMPORT - 201 (PORT - 2) U.S. IND/EU CTA IMP
Portage Biotech — Investor Presentation (January 2023) on 6ix